Nautilus to Measure Proteoforms Driving Alzheimer’s Disease and Cancer in ARPA-H-Funded SEEDS Consortium

Nautilus Biotechnology announced it will receive up to $6 million as part of a $51.7 million ARPA-H-funded SEEDS consortium led by Buck Institute and Georgetown University. The consortium aims to predict protein misfolding and develop diagnostics and therapeutics for neurodegenerative diseases and cancer. Nautilus will deploy its Voyager Platform to measure proteoforms in Alzheimer's disease and Ewing sarcoma research.